Clinical trial results to date have demonstrated significant improvements in near vision and a superior safety profile, supporting potential quality of life improvement in people with presbyopia. In a Phase 2b study, CSF-1 demonstrated exceptional near visual acuity with NO reduction of distance or night vision. This study also met the primary end-point, 3-line improvement in near vision (using the standard ETDRS chart).